A Multiomics Study Based on the Dynamic Evolution of Endometrial Carcinogenesis
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- the Dynamic Evolution of Endometrial Carcinogenesis
- Sponsor
- RenJi Hospital
- Enrollment
- 300
- Primary Endpoint
- Differences in the expression of these mutant genes among the three groups of participants as assessed by SAS® 9.4
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The goal of this observational study is to draw the characteristic maps of imaging omics, genomics, transcriptome, proteomics, pathological omics, metabolomics, etc. of the dynamic evolution of endometrial carcinogenesis in 100 patients with normal endometrium, 100 patients with atypical endometrial hyperplasia, and 100 patients with endometrial cancer; and then to explore the underlying molecular mechanism, and establish the database system for the dynamic evolution of endometrial carcinogenesis.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Pathological diagnosis: normal endometrium, atypical hyperplasia endometrium, or endometrial cancer;
- •Obtain pathological results after undergoing hysteroscopic surgery or hysterectomy;
- •The patient voluntarily participated in this research project with good compliance and was able to complete the enrollment according to the experimental requirements;
- •Sign the informed consent form and consent to the collection and use of their data, and consent to genomics, transcriptome and other tests.
Exclusion Criteria
- •Patients with malignant tumors in other parts of the body;
- •Suffering from uncontrollable neurological diseases, psychiatric diseases, or psychiatric disorders;
- •Poor compliance and inability to cooperate and describe treatment responders.
Outcomes
Primary Outcomes
Differences in the expression of these mutant genes among the three groups of participants as assessed by SAS® 9.4
Time Frame: January 2026 to June 2026
The mutant genes of participants and their expression as assessed by gene sequencing, RNA sequencing and mass spectrometry analysis
Time Frame: August 2023 to June 2026